About ibrutinib
Bruton tyrosine kinase inhibitor
Used for
- Chronic lymphocytic leukaemia and small lymphocytic lymphoma
- Waldenström macroglobulinaemia
- Mantle cell lymphoma
- Chronic graft-versus-host disease
Usual adult dose
Usually 420 mg once daily for chronic lymphocytic leukaemia, small lymphocytic lymphoma, or Waldenström macroglobulinaemia; other conditions may use different doses.
Usual dose in children
For chronic graft-versus-host disease in children aged 1 year and older, dosing is based on body surface area; specialist supervision is required.
Common side effects
- Diarrhoea, tiredness, muscle or joint pain
- Bruising, bleeding, or low blood counts
- Infections
- High blood pressure or irregular heartbeat
Important warnings
- Can cause serious bleeding, infections, and heart rhythm problems.
- Regular blood tests and blood pressure monitoring are needed.
- May increase risk of other cancers, including skin cancer.
- Do not stop or change treatment without the prescribing specialist.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for one month after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Strong CYP3A inhibitors can raise ibrutinib levels; some require avoiding or adjusting treatment.
- CYP3A inducers, such as rifampicin, can reduce its effect.
- Blood thinners and antiplatelet medicines can increase bleeding risk.
- Grapefruit and Seville oranges can affect ibrutinib levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.